1.Serotonin as a New Therapeutic Target for Diabetes Mellitus and Obesity.
Chang Myung OH ; Sangkyu PARK ; Hail KIM
Diabetes & Metabolism Journal 2016;40(2):89-98
Serotonin (5-hydroxytryptamine [5-HT]) is a monoamine that has various functions in both neuronal and non-neuronal systems. In the central nervous system, 5-HT regulates mood and feeding behaviors as a neurotransmitter. Thus, there have been many trials aimed at increasing the activity of 5-HT in the central nervous system, and some of the developed methods are already used in the clinical setting as anti-obesity drugs. Unfortunately, some drugs were withdrawn due to the development of unwanted peripheral side effects, such as valvular heart disease and pulmonary hypertension. Recent studies revealed that peripheral 5-HT plays an important role in metabolic regulation in peripheral tissues, where it suppresses adaptive thermogenesis in brown adipose tissue. Inhibition of 5-HT synthesis reduced the weight gain and improved the metabolic dysfunction in a diet-induced obesity mouse model. Genome-wide association studies also revealed genetic associations between the serotonergic system and obesity. Several genetic polymorphisms in tryptophan hydroxylase and 5-HT receptors were shown to have strong associations with obesity. These results support the clinical significance of the peripheral serotonergic system as a therapeutic target for obesity and diabetes.
Adipose Tissue, Brown
;
Animals
;
Anti-Obesity Agents
;
Central Nervous System
;
Diabetes Mellitus*
;
Feeding Behavior
;
Genome-Wide Association Study
;
Heart Valve Diseases
;
Hypertension, Pulmonary
;
Mice
;
Neurons
;
Neurotransmitter Agents
;
Obesity*
;
Polymorphism, Genetic
;
Receptors, Serotonin
;
Serotonin*
;
Thermogenesis
;
Tryptophan Hydroxylase
;
Weight Gain
2.Serotonergic Regulation of Hepatic Energy Metabolism
Jiwon PARK ; Wooju JEONG ; Chahyeon YUN ; Hail KIM ; Chang-Myung OH
Endocrinology and Metabolism 2021;36(6):1151-1160
The liver is a vital organ that regulates systemic energy metabolism and many physiological functions. Nonalcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease and end-stage liver failure. NAFLD is primarily caused by metabolic disruption of lipid and glucose homeostasis. Serotonin (5-hydroxytryptamine [5-HT]) is a biogenic amine with several functions in both the central and peripheral systems. 5-HT functions as a neurotransmitter in the brain and a hormone in peripheral tissues to regulate systemic energy homeostasis. Several recent studies have proposed various roles of 5-HT in hepatic metabolism and inflammation using tissue-specific knockout mice and 5-HT-receptor agonists/antagonists. This review compiles the most recent research on the relationship between 5-HT and hepatic metabolism, and the role of 5-HT signaling as a potential therapeutic target in NAFLD.
3.Serotonin Regulates De Novo Lipogenesis in Adipose Tissues through Serotonin Receptor 2A
Ko Eun SHONG ; Chang-Myung OH ; Jun NAMKUNG ; Sangkyu PARK ; Hail KIM
Endocrinology and Metabolism 2020;35(2):470-479
Background:
Obesity is defined as excessive fat mass and is a major cause of many chronic diseases such as diabetes, cardiovascular disease, and cancer. Increasing energy expenditure and regulating adipose tissue metabolism are important targets for the treatment of obesity. Serotonin (5-hydroxytryptophan [5-HT]) is a monoamine metabolite of the essential amino acid tryptophan. Here, we demonstrated that 5-HT in mature adipocytes regulated energy expenditure and lipid metabolism.
Methods:
Tryptophan hydroxylase 1 (TPH1) is the rate-limiting enzyme during 5-HT synthesis in non-neural peripheral tissues. We generated adipose tissue-specific Tph1 knockout (Tph1 FKO) mice and adipose tissue-specific serotonin receptor 2A KO (Htr2a FKO) mice and analyzed their phenotypes during high-fat diet (HFD) induced obesity.
Results:
Tph1 FKO mice fed HFD exhibited reduced lipid accumulation, increased thermogenesis, and resistance to obesity. In addition, Htr2a FKO mice fed HFD showed reduced lipid accumulation in white adipose tissue and resistance to obesity.
Conclusion
These data suggest that the inhibition of serotonin signaling might be an effective strategy in obesity.
5.Essential Role of Protein Arginine Methyltransferase 1 in Pancreas Development by Regulating Protein Stability of Neurogenin 3
Kanghoon LEE ; Hyunki KIM ; Joonyub LEE ; Chang Myung OH ; Heein SONG ; Hyeongseok KIM ; Seung Hoi KOO ; Junguee LEE ; Ajin LIM ; Hail KIM
Diabetes & Metabolism Journal 2019;43(5):649-658
BACKGROUND: Protein arginine methyltransferase 1 (PRMT1) is a major enzyme responsible for the formation of methylarginine in mammalian cells. Recent studies have revealed that PRMT1 plays important roles in the development of various tissues. However, its role in pancreas development has not yet been elucidated. METHODS: Pancreatic progenitor cell-specific Prmt1 knock-out (Prmt1 PKO) mice were generated and characterized for their metabolic and histological phenotypes and their levels of Neurog3 gene expression and neurogenin 3 (NGN3) protein expression. Protein degradation assays were performed in mPAC cells. RESULTS: Prmt1 PKO mice showed growth retardation and a severely diabetic phenotype. The pancreatic size and β-cell mass were significantly reduced in Prmt1 PKO mice. Proliferation of progenitor cells during the secondary transition was decreased and endocrine cell differentiation was impaired. These defects in pancreas development could be attributed to the sustained expression of NGN3 in progenitor cells. Protein degradation assays in mPAC cells revealed that PRMT1 was required for the rapid degradation of NGN3. CONCLUSION: PRMT1 critically contributes to pancreas development by destabilizing the NGN3 protein.
Animals
;
Diabetes Mellitus
;
Endocrine Cells
;
Gene Expression
;
Islets of Langerhans
;
Mice
;
Pancreas
;
Phenotype
;
Protein Stability
;
Protein-Arginine N-Methyltransferases
;
Proteolysis
;
Stem Cells
6.Inhibition of Serotonin Synthesis Induces Negative Hepatic Lipid Balance.
Jun NAMKUNG ; Ko Eun SHONG ; Hyeongseok KIM ; Chang Myung OH ; Sangkyu PARK ; Hail KIM
Diabetes & Metabolism Journal 2018;42(3):233-243
BACKGROUND: Hepatic steatosis is caused by metabolic stress associated with a positive lipid balance, such as insulin resistance and obesity. Previously we have shown the anti-obesity effects of inhibiting serotonin synthesis, which eventually improved insulin sensitivity and hepatic steatosis. However, it is not clear whether serotonin has direct effect on hepatic lipid accumulation. Here, we showed the possibility of direct action of serotonin on hepatic steatosis. METHODS: Mice were treated with para-chlorophenylalanine (PCPA) or LP-533401 to inhibit serotonin synthesis and fed with high fat diet (HFD) or high carbohydrate diet (HCD) to induce hepatic steatosis. Hepatic triglyceride content and gene expression profiles were analyzed. RESULTS: Pharmacological and genetic inhibition of serotonin synthesis reduced HFD-induced hepatic lipid accumulation. Furthermore, short-term PCPA treatment prevented HCD-induced hepatic steatosis without affecting glucose tolerance and browning of subcutaneous adipose tissue. Gene expression analysis revealed that the expressions of genes involved in de novo lipogenesis and triacylglycerol synthesis were downregulated by short-term PCPA treatment as well as long-term PCPA treatment. CONCLUSION: Short-term inhibition of serotonin synthesis prevented hepatic lipid accumulation without affecting systemic insulin sensitivity and energy expenditure, suggesting the direct steatogenic effect of serotonin in liver.
Animals
;
Diabetes Mellitus
;
Diet
;
Diet, High-Fat
;
Energy Metabolism
;
Fatty Liver
;
Fenclonine
;
Gene Expression
;
Glucose
;
Insulin Resistance
;
Lipogenesis
;
Liver
;
Mice
;
Obesity
;
Serotonin*
;
Stress, Physiological
;
Subcutaneous Fat
;
Transcriptome
;
Triglycerides
7.The Role of Serotonin in Ventricular Repolarization in Pregnant Mice.
Shanyu CUI ; Hyewon PARK ; Hyelim PARK ; Dasom MUN ; Seung Hyun LEE ; Hyoeun KIM ; Nuri YUN ; Hail KIM ; Michael KIM ; Hui Nam PAK ; Moon Hyoung LEE ; Boyoung JOUNG
Yonsei Medical Journal 2018;59(2):279-286
PURPOSE: The mechanisms underlying repolarization abnormalities during pregnancy are not fully understood. Although maternal serotonin (5-hydroxytryptamine, 5-HT) production is an important determinant for normal fetal development in mice, its role in mothers remains unclear. We evaluated the role of serotonin in ventricular repolarization in mice hearts via 5Htr3 receptor (Htr3a) and investigated the mechanism of QT-prolongation during pregnancy. MATERIALS AND METHODS: We measured current amplitudes and the expression levels of voltage-gated K⁺ (Kv) channels in freshly-isolated left ventricular myocytes from wild-type non-pregnant (WT-NP), late-pregnant (WT-LP), and non-pregnant Htr3a homozygous knockout mice (Htr3a(−/−)-NP). RESULTS: During pregnancy, serotonin and tryptophan hydroxylase 1, a rate-limiting enzyme for the synthesis of serotonin, were markedly increased in hearts and serum. Serotonin increased Kv current densities concomitant with the shortening of the QT interval in WT-NP mice, but not in WT-LP and Htr3a(−/−)-NP mice. Ondansetron, an Htr3 antagonist, decreased Kv currents in WT-LP mice, but not in WT-NP mice. Kv4.3 directly interacted with Htr3a, and this binding was facilitated by serotonin. Serotonin increased the trafficking of Kv4.3 channels to the cellular membrane in WT-NP. CONCLUSION: Serotonin increases repolarizing currents by augmenting Kv currents. Elevated serotonin levels during pregnancy counterbalance pregnancy-related QT prolongation by facilitating Htr3-mediated Kv currents.
*Action Potentials/drug effects
;
Animals
;
Cell Membrane/drug effects/metabolism
;
Disease Models, Animal
;
Electrocardiography
;
Female
;
HSC70 Heat-Shock Proteins/metabolism
;
HSP90 Heat-Shock Proteins/metabolism
;
Heart Ventricles/drug effects/*metabolism
;
Mice, Inbred C57BL
;
Mice, Knockout
;
Myocytes, Cardiac/drug effects/metabolism
;
Potassium Channels/metabolism
;
Pregnancy
;
Rabbits
;
Rats, Sprague-Dawley
;
Receptors, Serotonin, 5-HT3/metabolism
;
Serotonin/*metabolism
;
Serotonin 5-HT3 Receptor Agonists/pharmacology